Syndax Presents Data From Pivotal AUGMENT-101 Trial Of Revumenib In Relapsed/Refractory KMT2Ar Acute Leukemia At Oral Presentation During ASH Meeting; Trial Met Its Primary Endpoint At Interim Analysis Of The Pooled KMT2Ar AML And ALL Cohorts
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals (NASDAQ:SNDX) presented positive data from the AUGMENT-101 trial of revumenib for relapsed/refractory KMT2Ar acute leukemia at the ASH Meeting. The trial met its primary endpoint, showing a 63% overall response rate and a median overall survival of 8.0 months. The treatment was well tolerated with low discontinuation rates. Syndax plans to submit a New Drug Application for revumenib to the FDA by year-end.
December 12, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals reported successful trial results for revumenib, with plans to submit an FDA application, indicating potential positive short-term impact on SNDX stock.
The positive trial results and the upcoming FDA application submission for revumenib are significant milestones for Syndax. These developments are likely to be viewed favorably by investors, potentially leading to a short-term increase in SNDX's stock price. The data presented shows a strong efficacy and safety profile for revumenib, which could lead to increased investor confidence in the company's pipeline.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100